Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Immunovant, Inc. Common Stock | IMVT

AI Analysis of Immunovant, Inc. Common Stock

There wasn't too much excitement in Immunovant today which only managed to move up 0.82% on the day.

It looks like Immunovant isn't currently at a very decisive point in regards to support/resistance levels. But let's also consider momentum! Immunovant has had a nice run over the last year and provided good returns to shareholders. Over the previous year, the asset has grown 114.08 percent which isn't too bad. It may find some support around the $35.62 price level in the near term.


Last analyzed on 2026-07-23

Companies with the highest correlation to Immunovant

Company Score 1 Day% 5 Day 1 Month 3 Month 6 Month 1 Year RSI 3mo S-momo ? 6mo S-momo 1yr S-momo Resistance ? Support Demark Sell ? Demark Buy Short Interest Score
TGTX | TG Therapeutics, Inc.0.845.351.153.4960.5075.4747.6129114.7262.7548.03-1931.43164.800020.848
VKTX | Viking Therapeutics, Inc0.81-5.15-4.56-4.339.263.815.964415.0324.7427.88-1322.81-14237.700012.0297
ARQT | Arcutis Biotherapeutics, 0.78-2.04-4.072.4017.352.5583.305614.5915.3427.15296.53-29787.48000
ARWR | Arrowhead Research Corpor0.75-2.1616.809.4723.7424.70445.105774.6644.62104.550.00-28267.88007.83995

Top 3 correlating companies

See full charts for all peers

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-